Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Adicionar filtros








Intervalo de ano
1.
Chinese Journal of Endocrinology and Metabolism ; (12): 683-688, 2023.
Artigo em Chinês | WPRIM | ID: wpr-994376

RESUMO

Objective:To explore the clinical and genetic characteristics of 5α-reductase 2 deficiency syndrome(5α-RD2).Methods:Retrospective analysis of three cases of 5α-RD2 to summarize clinical data. Genetic testing was conducted using chromosome karyotyping analysis, whole-exome sequencing(WES), Sanger sequencing, and bioinformatics analysis. The effect of the novel variant on the structure of the 5α-reductase was evaluated by studying the homology modeling structure using SWISSMODEL and PyMoL.Results:The patients of all three cases have social gender as female. In Case 1, a 6-year-old patient sought medical attention due to abnormal external genitalia development. In Cases 2 and 3, 15-year-old patients presented with primary amenorrhea, and they showed masculinization of secondary sexual characteristics during puberty. In all three cases, the external genitalia exhibited varying degrees of masculinization, with clitoromegaly resembling a small penis and accompanying cryptorchidism. In Case 2, an hCG stimulation test was performed, and the testosterone/dihydrotestosterone(DHT) ratio was found to be 17.4. The karyotype of all three patients was 46, XY. Whole-exome sequencing(WES) detected SRD5A2 gene variants in all cases, with genotypes being p. Gln6Ter/p.Arg227Gln, p. Gln6Ter/p.Pro250Ala, and p. Arg227Ter/p.His89Tyr, respectively. Parental validation confirmed compound heterozygous mutations in all cases. The novel variant p. Pro250Ala was identified and classified as a likely pathogenic variant according to ACMG guidelines. Protein modeling analysis indicated that this variant may affect the binding of 5α-reductase 2 to NADPH. In Case 1, male gender was chosen, and a laparoscopic bilateral orchiopexy was performed. In Case 2, female gender was chosen, and testectomy and vaginoplasty were performed. The gender selection for Case 3 has not been definitively determined yet.Conclusions:Abnormal external genitalia is a common phenotype of 5α-RD2. After hCG stimulation test, there is a significant increase in the testosterone/dihydrotestosterone(DHT) ratio, which indicates that Sanger sequencing of the SRD5A2 gene can be directly performed. 5α-RD2 exhibits significant clinical heterogeneity, and WES can facilitate the differential diagnosis of 46, XY disorders of sex development. The study also reported a novel variant, p. Pro250Ala, which enriches the SRD5A2 gene variant database.

2.
Chinese Journal of Natural Medicines (English Ed.) ; (6): 518-526, 2022.
Artigo em Inglês | WPRIM | ID: wpr-939916

RESUMO

Benign prostatic hyperplasia (BPH) is a chronic male disease characterized by the enlarged prostate. Celtis chosenianaNakai (C. choseniana) is medicinally used to alleviate pain, gastric disease, and lung abscess. In this study, the effect of C. choseniana extract on BPH was investigated using testosterone-induced rats. Sprague Dawley rats were divided into five groups: control, BPH (testosterone 5 mg·kg-1), Fina (finasteride 2 mg·kg-1), and C. choseniana (50 and 100 mg·kg-1). After four weeks of TP treatment with finasteride or C. choseniana, prostate weights and DHT levels were measured. In addition, the prostates were histopathologically examined and measured for protein kinase B (Akt)/nuclear factor-κB (NF-κB)/AR signaling, proliferation, apoptosis, and autophagy. Prostate weight and epithelial thickness were reduced in the C. choseniana groups compared with that in the BPH group. The extract of C. choseniana acted as a 5α reductase inhibitor, reducing DHT levels in the prostate. Furthermore, the extract of C. choseniana blocked the activation of p-Akt, nuclear NF-κB activation and reduced the expression of AR and PSA compared with BPH. Moreover, the expression of Bax, PARP-1, and p53 increased, while the expression of bcl-2 decreased. The present study demonstrated that C. choseniana extract alleviated testosterone-induced BPH by suppressing 5α reductase and Akt/NF-κB activation, reducing AR signaling and inducing apoptosis and autophagy in the prostate. These results suggested that C. choseniana probably contain potential herbal agents to alleviate BPH.


Assuntos
Animais , Masculino , Ratos , Colestenona 5 alfa-Redutase/metabolismo , Finasterida/efeitos adversos , NF-kappa B/genética , Extratos Vegetais/uso terapêutico , Hiperplasia Prostática/tratamento farmacológico , Proteínas Proto-Oncogênicas c-akt/genética , Ratos Sprague-Dawley , Receptores Androgênicos/metabolismo , Testosterona , Ulmaceae/metabolismo
3.
Asian Journal of Andrology ; (6): 577-581, 2019.
Artigo em Inglês | WPRIM | ID: wpr-1009726

RESUMO

In this study, we investigated the genetics, clinical features, and therapeutic approach of 14 patients with 5α-reductase deficiency in China. Genotyping analysis was performed by direct sequencing of PCR products of the steroid 5α-reductase type 2 gene (SRD5A2). The 5α-reductase activities of three novel mutations were investigated by mutagenesis and an in vitro transfection assay. Most patients presented with a microphallus, variable degrees of hypospadias, and cryptorchidism. Eight of 14 patients (57.1%) were initially reared as females and changed their social gender from female to male after puberty. Nine mutations were identified in the 14 patients. p.G203S, p.Q6X, and p.R227Q were the most prevalent mutations. Three mutations (p.K35N, p.H162P, and p.Y136X) have not been reported previously. The nonsense mutation p.Y136X abolished enzymatic activity, whereas p.K35N and p.H162P retained partial enzymatic activity. Topical administration of dihydrotestosterone during infancy or early childhood combined with hypospadia repair surgery had good therapeutic results. In conclusion, we expand the mutation profile of SRD5A2 in the Chinese population. A rational clinical approach to this disorder requires early and accurate diagnosis, especially genetic diagnosis.


Assuntos
Adolescente , Adulto , Criança , Pré-Escolar , Humanos , Masculino , Adulto Jovem , 3-Oxo-5-alfa-Esteroide 4-Desidrogenase/genética , Povo Asiático/genética , China , Transtorno 46,XY do Desenvolvimento Sexual/genética , Hormônio Foliculoestimulante/sangue , Genitália Masculina/anormalidades , Hipospadia/genética , Hormônio Luteinizante/sangue , Proteínas de Membrana/genética , Mutação/genética , Alinhamento de Sequência , Erros Inatos do Metabolismo de Esteroides/genética , Testosterona/sangue
4.
Natural Product Sciences ; : 200-207, 2019.
Artigo em Inglês | WPRIM | ID: wpr-760572

RESUMO

Albizzia julibrissin (AJ) is an herbal medicine that shows low toxicity, promotes promoting blood circulation and mitigates the inflammation and has mild side effects. Benign prostate hyperplasia (BPH) is one of the most common diseases that occurs in older males and often results in lower urinary tract symptoms. This study was conducted to evaluate the protective effect of AJ against BPH using LNCaP cells and Sprague Dawley rats treated with testosterone. Treatment with AJ extract reduced the expression of androgen receptor (AR) and prostate-specific antigen (PSA) in vitro. In vivo, rats were divided into 6 groups: 1 (Normal Control); 2 (Testosterone propionate (TP) alone); 3 (TP + finasteride); 4 (TP + AJ 10 mg/kg); 5 (TP + AJ 50 mg/kg); 6 (TP + AJ 300 mg/kg). The groups treated with AJ showed reduced the relative prostate weights and BPH-related proteins were altered, with decreased AR, PSA and proliferating cell nuclear antigen (PCNA) observed by western blot. Histopathological analysis revealed the therapeutic effect of AJ, with a decreased thickness of epithelial cells and reduced level of PCNA and 5α-reductase type 2. These results suggest that AJ extract could ameliorate testosterone-induced benign prostatic hyperplasia.


Assuntos
Animais , Humanos , Masculino , Ratos , Albizzia , Circulação Sanguínea , Western Blotting , Dietilpropiona , Células Epiteliais , Medicina Herbária , Hiperplasia , Técnicas In Vitro , Inflamação , Sintomas do Trato Urinário Inferior , Antígeno Nuclear de Célula em Proliferação , Próstata , Antígeno Prostático Específico , Hiperplasia Prostática , Ratos Sprague-Dawley , Receptores Androgênicos , Testosterona , Pesos e Medidas
5.
International Journal of Pediatrics ; (6): 609-614, 2018.
Artigo em Chinês | WPRIM | ID: wpr-692554

RESUMO

5α-reductase type 2 deficiency (5α-RD2)is a monogenic genetic disease with autosomal recessive inheritance.It is a common type of 46,XY disorders of sex development and is caused by deficiency of 5α-reductase type 2.Due to the complex and diverse clinical presentations and nigher overlaps with other types of 46,XY DSD,it is difficult to diagnose.Early diagnosis and treatment may improve the prognosis.In this paper,we review the literature and summarize the progress of the diagnosis and treatment of 5α-reductase type 2 deficiency,aiming to facilitate clinical diagnosis and treatment of the disease.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA